1. Gastroduodenal mucosal defense mechanisms
   Hyder Said et al, 2015, Current Opinion in Gastroenterology CrossRef
2. Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism
   Shuihong Zheng et al, 2023, Applied Biochemistry and Biotechnology CrossRef
3. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns
   Soo Lim et al, 2018, Trends in Endocrinology & Metabolism CrossRef
4. Nutrition and Nonalcoholic Fatty Liver Disease
   Manu V. Chakravarthy et al, 2020, Gastroenterology Clinics of North America CrossRef
5. Rational design of oral delivery nanosystems for hypoglycemic peptides
   Taoxing Peng et al, 2023, Nano Today CrossRef
6. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
   Areti Sofogianni et al, 2020, World Journal of Hepatology CrossRef
7. Identification of genes regulated by lipids from seaweed Susabinori (Pyropia yezoensis) involved in the improvement of hepatic steatosis: Insights from RNA-Seq analysis in obese db/db mice
   Sayaka Iizasa et al, 2023, PLOS ONE CrossRef
8. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
   Mohammad S. Kuchay et al, 2020, Diabetologia CrossRef
9. Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease
   Chao-lin Li et al, 2015, Journal of Huazhong University of Science and Technology [Medical Sciences] CrossRef
10. Polyphenol-Rich Extracts of Xylopia and Aframomum Species Show Metabolic Benefits by Lowering Hepatic Lipid Accumulation in Diet-Induced Obese Mice
    Achille Parfait Nwakiban Atchan et al, 2022, ACS Omega CrossRef
11. Exendin‑4 inhibits lipotoxicity‑induced oxidative stress in β‑cells by inhibiting the activation of TLR4/NF‑κB signaling pathway
    Ximei Shen et al, 2020, International Journal of Molecular Medicine CrossRef
12. Wheat-bran autolytic peptides containing a branched-chain amino acid attenuate non-alcoholic steatohepatitis via the suppression of oxidative stress and the upregulation of AMPK/ACC in high-fat diet-fed mice
    Takumi Kawaguchi et al, 2017, International Journal of Molecular Medicine CrossRef
13. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Jun Sung Moon et al, 2022, Trends in Endocrinology & Metabolism CrossRef
14. Contribution of Macrophage Polarization to Metabolic Diseases
    Yoshihiro Komohara et al, 2016, Journal of Atherosclerosis and Thrombosis CrossRef
15. Role of bioactive fatty acids in nonalcoholic fatty liver disease
    Eva Juárez-Hernández et al, 2015, Nutrition Journal CrossRef
16. Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy
    M. Pilar Valdecantos et al, 2018, Scientific Reports CrossRef
17. Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes
    Orsu Prabhakar et al, 2021, Tzu Chi Medical Journal CrossRef
18. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease
    Manuel Soto-Catalán et al, 2024, International Journal of Molecular Sciences CrossRef